title: Methylprednisolone Pulse Treatment of Graves' Ophthalmopathy Is Not Associated with Secondary Adrenocortical Insufficiency.
abstract: OBJECTIVE
  Graves' ophthalmopathy (GO) is an inflammatory disease in the orbital region. The first-line medical treatment is glucocorticoids. An important potential side effect of glucocorticoid treatment is suppression of the hypothalamic-pituitary-adrenal (HPA) axis with impairment of endogenous cortisol production, implicating symptoms of adrenocortical insufficiency, especially in the period after cessation of therapy with possible risks in cases of intercurrent illness. The aim of this study was to evaluate HPA axis function before and after methylprednisolone pulse treatment of GO.
  
  
  METHODS
  HPA axis function was evaluated by measurements of plasma ACTH and an ACTH stimulation test with plasma cortisol measurements at 0 and 30 min after an intravenous bolus of synthetic ACTH (Synacthen® 250 µg). This was done in 12 patients with GO before and at cessation of methylprednisolone pulse treatment (500 mg i.v. per week for 6 weeks followed by 250 mg i.v. per week for an additional 6 weeks).
  
  
  RESULTS
  All patients included fulfilled the criteria of intact HPA axis function before and at cessation of methylprednisolone pulse treatment. Data are given as medians (with ranges). Before glucocorticoid treatment basal plasma cortisol was 290 nM (196-579) and 786 nM (612-1,050) after ACTH stimulation. At cessation of therapy the corresponding values were 309 nM (88-718) and 852 nM (524-1,011), respectively. Thus, all patients passed a 30-min stimulated plasma cortisol of 500 nM. Before treatment plasma ACTH was 4.2 pmol/l (4-16) and at cessation of therapy the corresponding value was 4.8 pmol/l (2-9; p = 0.27).
  
  
  CONCLUSIONS
  Transient suppression of the HPA axis with secondary adrenocortical insufficiency does not seem to be a common phenomenon after intravenous methylprednisolone pulse therapy for GO. Therefore, routine precautions are not necessary. However, our results do not exclude that transient secondary adrenocortical insufficiency might occur occasionally.
authors.affiliation: Department of Internal Medicine and Endocrinology, Copenhagen University Hospital, Herlev, Denmark.
authors.forename: Sofie
authors.initials: S
authors.lastname: Jespersen
authors.affiliation: Department of Internal Medicine and Endocrinology, Copenhagen University Hospital, Herlev, Denmark.
authors.forename: Birte
authors.initials: B
authors.lastname: Nygaard
authors.affiliation: Department of Internal Medicine and Endocrinology, Copenhagen University Hospital, Herlev, Denmark.
authors.forename: Lars Østergaard
authors.initials: LØ
authors.lastname: Kristensen
keywords: Adrenocortical insufficiency; Glucocorticoids; Graves’ ophthalmopathy; Methylprednisolone
references.citation: Support Care Cancer. 2012 Jul;20(7):1565-72
references.pmid: 21850416
references.citation: Clin Endocrinol (Oxf). 1997 Jul;47(1):9-14
references.pmid: 9302365
references.citation: Thorax. 2006 May;61(5):405-8
references.pmid: 16517576
references.citation: J Clin Endocrinol Metab. 2001 Aug;86(8):3562-7
references.pmid: 11502779
references.citation: Clin Endocrinol (Oxf). 2002 Apr;56(4):533-9
references.pmid: 11966747
references.citation: J Clin Endocrinol Metab. 2008 Nov;93(11):4245-53
references.pmid: 18697868
references.citation: Thyroid. 2015 Apr;25(4):462-3
references.pmid: 25602127
references.citation: Ann Intern Med. 2003 Aug 5;139(3):194-204
references.pmid: 12899587
references.citation: Cancer Treat Rep. 1979 Aug;63(8):1327-30
references.pmid: 383293
references.citation: Clin Rheumatol. 2014 Jan;33(1):99-103
references.pmid: 23982564
references.citation: Eur J Endocrinol. 2008 Mar;158(3):273-85
references.pmid: 18299459
references.citation: J Clin Endocrinol Metab. 1998 Jan;83(1):144-51
references.pmid: 9435432
references.citation: Pediatrics. 2012 Dec;130(6):e1512-9
references.pmid: 23147980
references.citation: J Rheumatol. 2000 Apr;27(4):911-8
references.pmid: 10782815
references.citation: Eur J Intern Med. 2013 Dec;24(8):714-20
references.pmid: 23806261
references.citation: N Engl J Med. 1992 Jan 23;326(4):226-30
references.pmid: 1309389
references.citation: Clin Endocrinol (Oxf). 2004 Sep;61(3):394-9
references.pmid: 15355458
references.citation: J Endocrinol Invest. 1996 Jan;19(1):30-4
references.pmid: 8851689
references.citation: Scand J Clin Lab Invest. 2002;62(1):33-7
references.pmid: 12002411
references.citation: Drug Saf. 2008;31(9):769-74
references.pmid: 18707191
references.citation: Am J Med. 1993 Sep;95(3):258-64
references.pmid: 8368224
references.citation: Lancet. 1979 Mar 24;1(8117):630-3
references.pmid: 85870
references.citation: J Clin Endocrinol Metab. 2012 Dec;97(12):4454-63
references.pmid: 23038682